Differential Contribution of NF-κB Signaling Pathways to CD4+ Memory T Cell Induced Activation of Endothelial Cells

Author
Kim Jeucken, Charlotte van Rooijen, Yik Kan, Lotte Kocken, Aldo Jongejan, Abraham van Steen, Jaap van Buul, Henric Olsson, Jan van Hamburg, Sander Tas
Keywords
Abstract

<p>Endothelial cells (ECs) are important contributors to inflammation in immune-mediated inflammatory diseases (IMIDs). In this study, we examined whether CD4<sup>+</sup> memory T (T<sub>m</sub>) cells can drive EC inflammatory responses. Human T<sub>m</sub> cells produced ligands that induced inflammatory responses in human umbilical vein EC as exemplified by increased expression of inflammatory mediators including chemokines and adhesion molecules. NF-κB, a key regulator of EC activation, was induced by T<sub>m</sub> cell ligands. We dissected the relative contribution of canonical and non-canonical NF-κB signaling to T<sub>m</sub> induced EC responses using pharmacological small molecule inhibitors of IKKβ (iIKKβ) or NF-κB inducing kinase (iNIK). RNA sequencing revealed substantial overlap in IKKβ and NIK regulated genes (n=549) that were involved in inflammatory and immune responses, including cytokines (IL-1β, IL-6, GM-CSF) and chemokines (CXCL5, CXCL1). NIK regulated genes were more restricted, as 332 genes were uniquely affected by iNIK versus 749 genes by iIKKβ, the latter including genes involved in metabolism, proliferation and leukocyte adhesion (VCAM-1, ICAM-1). The functional importance of NIK and IKKβ in EC activation was confirmed by transendothelial migration assays with neutrophils, demonstrating stronger inhibitory effects of iIKKβ compared to iNIK. Importantly, iIKKβ - and to some extent iNIK - potentiated the effects of currently employed therapies for IMIDs, like JAK inhibitors and anti-IL-17 antibodies, on EC inflammatory responses. These data demonstrate that inhibition of NF-κB signaling results in modulation of T<sub>m</sub> cell-induced EC responses and highlight the potential of small molecule NF-κB inhibitors as a novel treatment strategy to target EC inflammatory responses in IMIDs.</p>

Year of Publication
2022
Journal
Frontiers in immunology
Volume
13
Number of Pages
860327
Date Published
01/2022
ISSN Number
1664-3224
DOI
10.3389/fimmu.2022.860327
Alternate Journal
Front Immunol
PMCID
PMC9235360
PMID
35769477
Download citation
Reactivity
Human
Category
ELISA
Analyte
IL-6, TNF-α